Researchers have identified a gene that drives the development of tumours in over one per cent of all cancer patients. This is the first time that the gene CUX1 has been broadly linked to cancer development.

The team discovered that, when CUX1 is deactivated, a biological pathway is activated that increases tumour growth. Drugs that inhibit the biological pathway are currently being used in the clinic and are in development thus highlighting a potential new targeted therapy for patients with this type of cancer-causing mutation.

Around 300,000 people in the UK each year are diagnosed with cancer, and for more than 3,000 of these patients, an inactive CUX1 gene may be an underlying factor for their disease.

“Our research is a prime example of how understanding the genetic code of cancers can drive the search for targeted cancer therapies that work more effectively and efficiently, says Dr David Adams, lead author from the Wellcome Trust Sanger Institute. “This could improve the lives of thousands of people suffering from cancer.”

The team used genetic data from over 7,600 cancer patients, collected and sequenced by the International Cancer Genome Constortium (ICGC) and other groups. They found that in around one per cent of the cancer genomes studied, mutations deactivated CUX1, an event associated with tumour growth.

CUX1 is mutated at a relatively low frequency, but across many different types of cancer. Because previous studies focused on genes that are mutated at a high rate in one cancer type to find cancer drivers, CUX1 was missed as a driver of cancer.

“Our work harnesses the power of combining large-scale cancer genomics with experimental genetics,” says Dr Chi Wong, first author from the Wellcome Trust Sanger Institute and practising Haematologist at Addenbrooke’s Hospital. “CUX1 defects are particularly common in myeloid blood cancers, either through mutation or acquired loss of chromosome 7q. As these patients have a dismal prognosis currently, novel targeted therapies are urgently needed.”

“Data collected from large consortia such the ICGC, provides us with a new and broader way to identify genes that can underlie the development of cancers,” says Professor David Tuveson from Cold Spring Harbor Laboratory. “We can now look at cancers as groups of diseases according to their tissues of origin and collectively examine and compare their genomes.”

The team silenced CUX1 in cultured cells to understand how inactivating it might lead to the development of tumours. They found that when CUX1 is deactivated, it had a knock-on effect on a biological inhibitor, PIK3IP1, reducing its inhibitory effects. This mobilises an enzyme responsible for cell growth, phosphoinositide 3-kinase (PI3K), increasing the rate of tumour progression.

The team has already identified several dozen other genes that when mutated at a low frequency could promote cancer development. They plan to silence these genes in mice to fully understand how their inactivation may lead to cancer development and the mechanisms by which this occurs.

“Drugs that inhibit PI3K signalling are currently undergoing clinical trial,” says Professor Paul Workman, Deputy Chief Executive and Head of Cancer Therapeutics at The Institute of Cancer Research, London. “This discovery will help us to target these drugs to a new group of patients who will benefit from them and could have a dramatic effect on the lives of many cancer sufferers.”

###

Publication Details

Chi C. Wong, Inigo Martincorena3, Alistair G. Rust, Mamunur Rashid, Constantine Alifrangis, Ludmil B. Alexandrov, Jessamy C. Tiffen, Christina Kober, Chronic Myeloid

Disorders Working Group of the International Cancer Genome Consortium5, Anthony R. Green, Charles E. Massie, Jyoti Nangalia, Stella Lempidaki, Hartmut Döhner, Konstanze Döhner, Sarah J. Bray, Ultan McDermott, Elli Papaemmanuil, Peter J. Campbell & David J. Adams. (2013) ‘Inactivating CUX1 mutations promote tumorigenesis’

Advanced online publication in Nature Genetics 08 Dec 2013. Doi: 10.1038/ng.2846

Funding

A full list of funding can be found on the paper

Participating Centres

1. Experimental Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, Cambridge, CB10 1SA, UK.

2. Department of Haematology, University of Cambridge, Hills Road, Cambridge, CB2 0SP, UK.

3. The Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, Cambridge, CB10 1SA, UK.

4. Department of Biochemistry, Biocenter University of Würzberg, D-97074 Würzberg, Germany.

5. See Supplementary Note for members and affiliations,

6. Cambridge Institute for Medical Research, University of Cambridge, Hills Road, Cambridge, CB2 0SP, UK.

7. Wellcome Trust/MRC Stem Cell Institute, University of Cambridge, Cambridge, UK. Department of Physiology, Development and Neuroscience, University of Cambridge, CB2 3DY, UK.

10. Department of Internal Medicine III, University of Ulm, Albert-Einstein-Allee 23 89081, Ulm, Germany.

Selected Websites

The Wellcome Trust Sanger Institute is one of the world’s leading genome centres. Through its ability to conduct research at scale, it is able to engage in bold and long-term exploratory projects that are designed to influence and empower medical science globally. Institute research findings, generated through its own research programmes and through its leading role in international consortia, are being used to develop new diagnostics and treatments for human disease.

###

Aileen Sheehy
.(JavaScript must be enabled to view this email address)
44-012-234-92368
Wellcome Trust Sanger Institute